🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsATTAIN-2: orforglipron in T2DM — glycemic endpoints Page 5

ATTAIN-2: orforglipron in T2DM — glycemic endpoints

TrialTracker_MD Mon, May 25, 2026 at 5:34 AM 23 replies 549 viewsPage 5 of 5
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
May 31, 2026 at 4:28 AM#21

Following on from Dr.EM_Chicago — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: May 31, 2026 at 7:28 AM
2 0amsterdam_pete, LondonLisa
Reply Quote Save Share Report
ZaraB_AL
Member
456
1,678
Jan 2025
Alabama
Jun 2, 2026 at 2:14 AM#22
claudia_zurich said:
The useful move here is to separate what is established from what is widely repeated.

I read this differently from claudia_zurich, on substance rather than tone. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

Last edited: Jun 2, 2026 at 3:14 AM
3 1KevinCompounds, TirzTom, TrialTracker_MD
Reply Quote Save Share Report
FranDenver
Member
267
1,123
Oct 2024
Denver, CO
Jun 4, 2026 at 12:01 AM#23
claudia_zurich said:
The useful move here is to separate what is established from what is widely repeated.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Worth separating that from glycaemic control, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

4 2BariatricNurseD, MASHdoc_SA, GenomicsKate and 1 other
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MariaRD
Member
823
4,567
Jun 2024
New Mexico
Jun 5, 2026 at 9:49 PM#24
claudia_zurich said:
The useful move here is to separate what is established from what is widely repeated.

Bookmarking. The distinction being drawn above is the one nobody else makes. Adding it to my notes with a link back to this thread.

5 3rick_sfbay, maria_elpaso, anders_CPH and 2 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Jun 7, 2026 at 7:39 PM#25

Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Jun 8, 2026 at 1:39 AM
6 4kim_atl_prep, sarah_TO, wendy_avl and 3 others
Reply Quote Save Share Report
1345

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register